{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:42:32Z","timestamp":1790948552814,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Platelet C-type lectin-like receptor 2 (CLEC-2) is a hem-immunoreceptor tyrosine\u2013based activation motif-containing receptor that has a critical role in venous thrombosis but minimal involvement in hemostasis. CLEC-2 can be blocked by Btk inhibitors. Treatment with ibrutinib is associated with increased bleeding due to off-target inhibition of Src family kinases (SFKs). Patients with X-linked agammaglobulinemia (XLA) who lack Btk, however, do not bleed, suggesting selective Btk inhibition as a viable antithrombotic strategy. We assessed the effects of selective Btk inhibitors PRN1008 (rilzabrutinib) and PRN473 on platelet signaling and function mediated by CLEC-2 and glycoprotein-VI. We used healthy donors and XLA platelets to determine off-target inhibitor effects. Inferior vena cava (IVC) stenosis and Salmonella infection mouse models were used to assess antithrombotic effects of PRN473 in\u00a0vivo. PRN1008 and PRN473 potently inhibited CLEC-2\u2013mediated platelet activation to rhodocytin. No off-target inhibition of SFKs was seen. PRN1008 treatment of Btk-deficient platelets resulted in minor additional inhibition of aggregation and tyrosine phosphorylation, likely reflecting inhibition of Tec. No effect on G protein-coupled receptor-mediated platelet function was observed. PRN473 significantly reduced the number of thrombi in podoplanin-positive vessels after Salmonella infection and the presence of IVC thrombosis after vein stenosis. The potent inhibition of human platelet CLEC-2 and reduced thrombosis in in\u00a0vivo models, together with the lack of off-target SFK inhibition and absence of bleeding reported in rilzabrutinib-treated patients with immune thrombocytopenia, suggest Btk inhibition as a promising antithrombotic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012713","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T13:09:59Z","timestamp":1720184999000},"page":"5557-5570","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Selective Btk inhibition by PRN1008\/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice"],"prefix":"10.1182","volume":"8","author":[{"given":"Christopher W.","family":"Smith","sequence":"first","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Campos","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena C.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Jooss","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"2Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa-Sindi","family":"Ivanova","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-5192","authenticated-orcid":false,"given":"Maan","family":"Harbi","sequence":"additional","affiliation":[{"name":"3Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-8127","authenticated-orcid":false,"given":"Lourdes","family":"Garcia-Quintanilla","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Jossi","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Perez-Toledo","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Rookes","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-0390","authenticated-orcid":false,"given":"Alexander","family":"Brill","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-5865","authenticated-orcid":false,"given":"Lindsay N.","family":"Theodore","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7651-2203","authenticated-orcid":false,"given":"Tim","family":"Owens","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"LaStant","sequence":"additional","affiliation":[{"name":"6Principia Biopharma, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Foulke","sequence":"additional","affiliation":[{"name":"6Principia Biopharma, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Mukai","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Francesco","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Storek","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hicks","sequence":"additional","affiliation":[{"name":"5Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Langrish","sequence":"additional","affiliation":[{"name":"6Principia Biopharma, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Nunn","sequence":"additional","affiliation":[{"name":"6Principia Biopharma, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam F.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhi","family":"Chauhan","sequence":"additional","affiliation":[{"name":"4Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-7423","authenticated-orcid":false,"given":"Steve P.","family":"Watson","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-2975","authenticated-orcid":false,"given":"Phillip L. R.","family":"Nicolson","sequence":"additional","affiliation":[{"name":"1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"9","key":"2024111214110608600_bib1","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/bloodadvances.2020003377","article-title":"Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice","volume":"5","author":"Campos","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2024111214110608600_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"12","key":"2024111214110608600_bib3","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI79070","article-title":"Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets","volume":"125","author":"Hitchcock","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"14","key":"2024111214110608600_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2016-09-742999","article-title":"Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis","volume":"129","author":"Payne","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024111214110608600_bib5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41467-020-15584-3","article-title":"The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure","volume":"11","author":"Chauhan","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"2024111214110608600_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/09537104.2020.1775189","article-title":"A\u00a0rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors","volume":"31","author":"Nicolson","year":"2020","journal-title":"Platelets"},{"issue":"10","key":"2024111214110608600_bib7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1538-7836.2010.04006.x","article-title":"CLEC-2 is not required for platelet aggregation at arteriolar shear","volume":"8","author":"Hughes","year":"2010","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"32","key":"2024111214110608600_bib8","doi-asserted-by":"crossref","first-page":"24494","DOI":"10.1074\/jbc.M110.130575","article-title":"Essential in\u00a0vivo roles of the C-type lectin receptor CLEC-2 embryonic\/neonatal lethality of CLEC-2-deficient mice by blood\/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets","volume":"285","author":"Suzuki-Inoue","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"2024111214110608600_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1538-7836.2009.03451.x","article-title":"The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets","volume":"7","author":"SPALTON","year":"2009","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"12","key":"2024111214110608600_bib10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2024111214110608600_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"issue":"25","key":"2024111214110608600_bib12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2021012277","article-title":"Antiplatelet drugs block platelet activation by VITT patient serum","volume":"138","author":"Smith","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024111214110608600_bib13","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/jth.15899","article-title":"The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque\u2013induced thrombus formation and platelet procoagulant activity","volume":"20","author":"Smith","year":"2022","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"3","key":"2024111214110608600_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.16209","article-title":"Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib","volume":"187","author":"Kander","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2024111214110608600_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"2024111214110608600_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management, and risk reduction strategies","volume":"15","author":"Shatzel","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2024111214110608600_bib17","first-page":"1663","article-title":"Rapid tyrosine phosphorylation and activation of Bruton\u2019s tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking","volume":"95","author":"Oda","year":"2000","journal-title":"Blood"},{"issue":"26","key":"2024111214110608600_bib18","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2024111214110608600_bib19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024111214110608600_bib20","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"2024111214110608600_bib21","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J\u00a0Med Chem"},{"issue":"7","key":"2024111214110608600_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4049\/immunohorizons.2100063","article-title":"Preclinical mechanisms of topical PRN473, a Bruton tyrosine kinase inhibitor, in immune-mediated skin disease models","volume":"5","author":"Xing","year":"2021","journal-title":"Immunohorizons"},{"issue":"11","key":"2024111214110608600_bib23","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/jth.15836","article-title":"Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque\u2013induced GPVI clustering, signaling, and thrombus formation","volume":"20","author":"Jooss","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"2024111214110608600_bib24","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1182\/blood.2022015787","article-title":"Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice","volume":"139","author":"Mwiza","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2024111214110608600_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood.2021011871","article-title":"Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets","volume":"138","author":"Bye","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2024111214110608600_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A\u00a0role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"issue":"8","key":"2024111214110608600_bib27","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.jtha.2023.04.028","article-title":"Platelet glycoprotein VI cluster size is related to thrombus formation and phosphatidylserine exposure in collagen-adherent platelets under arterial shear","volume":"21","author":"Jooss","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"2024111214110608600_bib28","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque\u2013triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2024111214110608600_bib29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1055\/s-0039-1687877","article-title":"Btk inhibitors as first oral atherothrombosis-selective antiplatelet drugs?","volume":"119","author":"Busygina","year":"2019","journal-title":"Thromb Haemost"},{"issue":"11","key":"2024111214110608600_bib30","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A\u00a0phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton\u2019s tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5557\/2312548\/blooda_adv-2024-012713-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5557\/2312548\/blooda_adv-2024-012713-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:11:20Z","timestamp":1731402680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/21\/5557\/516848\/Selective-Btk-inhibition-by-PRN1008-PRN473-blocks"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":30,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012713","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}